JP2005528363A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528363A5
JP2005528363A5 JP2003578334A JP2003578334A JP2005528363A5 JP 2005528363 A5 JP2005528363 A5 JP 2005528363A5 JP 2003578334 A JP2003578334 A JP 2003578334A JP 2003578334 A JP2003578334 A JP 2003578334A JP 2005528363 A5 JP2005528363 A5 JP 2005528363A5
Authority
JP
Japan
Prior art keywords
hydroxyl
alkyl
formula
atom
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003578334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528363A (ja
Filing date
Publication date
Priority claimed from SE0200920A external-priority patent/SE0200920D0/xx
Application filed filed Critical
Publication of JP2005528363A publication Critical patent/JP2005528363A/ja
Publication of JP2005528363A5 publication Critical patent/JP2005528363A5/ja
Withdrawn legal-status Critical Current

Links

JP2003578334A 2002-03-25 2003-03-24 新規アダマンタン誘導体 Withdrawn JP2005528363A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200920A SE0200920D0 (sv) 2002-03-25 2002-03-25 Novel compounds
PCT/SE2003/000481 WO2003080579A1 (en) 2002-03-25 2003-03-24 Novel adamantane derivatives

Publications (2)

Publication Number Publication Date
JP2005528363A JP2005528363A (ja) 2005-09-22
JP2005528363A5 true JP2005528363A5 (enExample) 2006-05-18

Family

ID=20287392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003578334A Withdrawn JP2005528363A (ja) 2002-03-25 2003-03-24 新規アダマンタン誘導体

Country Status (8)

Country Link
US (2) US20050090524A1 (enExample)
EP (1) EP1490341A1 (enExample)
JP (1) JP2005528363A (enExample)
AR (1) AR039124A1 (enExample)
AU (1) AU2003216013A1 (enExample)
SE (1) SE0200920D0 (enExample)
TW (1) TW200306800A (enExample)
WO (1) WO2003080579A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
KR20060037258A (ko) * 2003-05-29 2006-05-03 아스트라제네카 아베 Ｐ2Ｘ7-수용체 길항제 및 종양 괴사 인자 α를 포함하는제약 조성물
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
WO2006024880A2 (en) * 2004-08-31 2006-03-09 Sylentis S.A.U. Methods and compositions to inhibit p2x7 receptor expression
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
WO2006136791A1 (en) * 2005-06-21 2006-12-28 Astrazeneca Ab Polymorphisms and haplotypes in p2x7 gene and their use in determining susceptibility for atherosclerosis-mediated diseases
US20100022531A1 (en) * 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
US20090298825A1 (en) * 2006-03-16 2009-12-03 Kelly Michael G Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
EP2001474B1 (en) * 2006-03-16 2016-03-09 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
WO2007109160A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
KR20090094336A (ko) * 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
DE602007008469D1 (de) * 2006-12-07 2010-09-23 Hoffmann La Roche 2-aminochinoline als 5-ht(5a)-rezeptorantagonisten
ES2388454T3 (es) 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
AU2009221389A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinoline derivatives
MX2010009643A (es) * 2008-03-07 2010-09-22 Hoffmann La Roche Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BRPI1014902A2 (pt) 2009-04-14 2016-04-19 Affectis Pharmaceuticals Ag composto antagonista de p2x7r, sua composição e seus usos
MX2012013075A (es) 2010-05-14 2012-12-17 Affectis Pharmaceuticals Ag Metodos novedosos para preparacion de antagonistas p2x7r.
CN102464631B (zh) * 2010-11-08 2016-08-10 中国科学院上海药物研究所 哌嗪取代的1,3-二取代脲类化合物及哌嗪取代的酰胺类化合物及其制备方法和用途
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
RU2014106611A (ru) 2011-07-22 2015-08-27 Актелион Фармасьютиклз Лтд Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
PL2931717T3 (pl) 2012-12-12 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
US9399623B2 (en) * 2014-06-05 2016-07-26 Merck Patent Gmbh Quinoline derivatives and their use in neurodegenerative diseases
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
AU682051B2 (en) * 1993-08-10 1997-09-18 James Black Foundation Limited Gastrin and CCK receptor ligands
CA2252531A1 (en) * 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO2000061569A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
KR100908468B1 (ko) * 2001-07-02 2009-07-21 엔.브이.오가논 테트라히드로퀴놀린 유도체
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
KR20060037258A (ko) * 2003-05-29 2006-05-03 아스트라제네카 아베 Ｐ2Ｘ7-수용체 길항제 및 종양 괴사 인자 α를 포함하는제약 조성물
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Similar Documents

Publication Publication Date Title
JP2005528363A5 (enExample)
EP3105220B1 (en) Process for manufacturing pyrimidine sulfamide derivatives
EP2186808A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
AU637015B2 (en) Dideoxydidehydrocarbocyclic pyrimidines
EP3473625B1 (en) Preparation method for chiral pyrrolopyrimidine compound
CN107771178A (zh) 杂环化合物的合成
CN101541818A (zh) 4’-叠氮基胞苷衍生物的制备方法
MX2008008447A (es) Proceso para la preparacion de imatinib.
AU2006258051B2 (en) Process for the synthesis of 5- (methyl-1H-imidazol-1-yl) -3- (tri fluorome th yl) -benzeneamine
CA2311540A1 (en) Process for the preparation of 8-methoxy-quinolone-carboxylic acids
CN114728923B (zh) 用于制备氧杂环丁烷-2-基甲胺的方法和中间体
AU2021300294A1 (en) Methods and intermediates for preparing JAK inhibitors
JP2010513410A (ja) アバカビルの調製方法
US7507738B2 (en) 5-protected aminopyrimidine compound, production method thereof and intermediate therefor
KR100273823B1 (ko) 5-치환된 사이토신 및 다른 4,5-이치환된 피리미딘-2(1h)-온의 제조방법
US7875722B2 (en) Method for producing quinolone carboxylic acid derivative
ES2955554T3 (es) Proceso para producir un derivado de purinona
US20220064205A1 (en) Process for the preparation of a cyclic dinucleotide
RU2187504C2 (ru) Четвертичная триметиламмонийная соль 1,3,5-триазина в качестве промежуточного продукта в синтезе модификатора-соотвердителя эпоксиолигомеров в композициях ангидридного отверждения
CN119954804B (zh) 嘧啶并[6,1-a]异喹啉-4-酮衍生物及其用途
JP5420549B2 (ja) エピポドフィロトキシンの（ポリ）アミノアルキルアミノアセトアミドの抗腫瘍性誘導体の合成方法
KR101012135B1 (ko) 발사르탄 메틸 에스테르의 제조방법
JP7145802B2 (ja) ２－アミノ－１，３，５－トリアジン化合物の製造方法
WO2025131978A1 (en) Drug-linker reagents for conjugation
CN106749266A (zh) 吡咯并[2,3‑d]嘧啶类化合物的高效制备方法